HIV-1 exists within individuals as a complex mixture of variants often referred to as a quasispecies. During the past 10 years, there have been many studies of the distribution and clinical significance of "low-abundance" or "minority" drug-resistance variants present in plasma in proportions below 20% to 30% -- the limit of detection of standard genotypic resistance testing using dideoxy-terminator "Sanger" sequencing. HIV-1 "deep" sequencing using NGS technologies have been widely used in research settings to study the clinical significance of low-abundance drug resistance mutations. In addition, NGS is commercially available for several niche clinical applications such as determining HIV-1 tropism before using a CCR5 inhibitor.
In this webinar, Dr. Shafer will review the scenarios in which low-abundance HIV-1 drug-resistance mutations are most clinically relevant, the most influential studies of NGS for HIV-1 drug resistance testing, and the practical aspects of NGS that have so far slowed its widespread adoption for most routine HIV-1 genotypic resistance testing.
This content is now FREE for all but, continuing education credit is not available.
Speaker: Robert W. Shafer MD
Duration: 1.0 hrs.
Level of Instruction: Basic
Reviewed: March, 2018
All sales are final. No refunds will be issued.
Members of AMP can access this webinar at no cost. Join the AMP Family!
June 18, 2015
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00